<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor(Harvard University), Mari Mino–Kenudson(Massachusetts General Hospital), James R. Stone(Harvard University), Jeffrey A. Engelman(Cancer Research Center), Christopher G. Azzoli(Massachusetts General Hospital), Subba R. Digumarthy(Massachusetts General Hospital), Yukako Yagi(Massachusetts General Hospital), Anna F. Farago(Massachusetts General Hospital), Ling Zhao(Huazhong Agricultural University), Zofia Piotrowska(Global Cancer Institute), Lecia V. Sequist(Harvard University), Alice T. Shaw(Dana-Farber Cancer Institute), Tiffany G. Huynh(Massachusetts General Hospital), Aaron N. Hata(Harvard University), Xiujun Fu(Shanghai Jiao Tong University), Katherine R. Schultz(Massachusetts General Hospital), Linnea Fulton(Massachusetts General Hospital), Teresa Morán(Institute of Agrifood Research and Technology), Ryan J. Sullivan(Dana-Farber Cancer Institute), Beow Y. Yeap(Harvard University), Emily Howe(Massachusetts General Hospital)
Cited by 1,234
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k